Another study of Botox for Migraines

July 6, 2007

Curtis Schreiber and Roger Cady reported their study at the recent annual meeting of the American Academy of Neurology. This was a randomized, double-blind, placebo controlled study Another study of Botox for migraines. Curtis Schreiber and Roger Cady reported their study at the recent annual meeting of the American Academy of Neurology. This was a randomized, double-blind, placebo controlled study (that is the most reliable kind of a study) of patients who had disabling headaches and had difficulty complying with their previous prophylactic treatment. 60 received Botox and 21 received placebo injections. There was a significant improvement in headache frequency, headache impact (so called HIT-6 measure) and treatment satisfaction in patients who received Botox compared to those who received placebo. There are about 100 published reports on the use of Botox for migraine headaches and the experience of most headache experts in the US is very positive. However, many insurance companies will not cover Botox because the FDA has not yet approved it for migraines. Allergan, the company that manufactures Botox is conducting the FDA-required trials (we at NYHC are participating in one of the two trials), but the earliest possible time for approval is 2009.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe